Project information | Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy TS ID 9716 | Guidance

Status	Topic selection
Technology type	Medicine
Decision	Awaiting decision
ID number	9716

Project Team

Project lead

Abbie Stephens

Email enquiries

If you have any queries please email Topic.Selection@nice.org.uk

Timeline

Key events during the development of the guidance:

Date	Update
11 September 2023	Topic selection. Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of TSID9716 - Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. For information, the company are not planning to submit to NICE at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
11 August 2022	Awaiting development. Status change linked to Topic Selection Decision being set to Selected

Date

Update

11 September 2023

Topic selection. Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of TSID9716 - Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. For information, the company are not planning to submit to NICE at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.

11 August 2022

Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on how we select topics for development, please see our page about topic selection